12 Month Price Forecast For ENGN
Distance to ENGN Price Forecasts
ENGN Price Momentum
๐ค Considering enGene (ENGN)?
Join 5,000+ investors getting our exclusive market analysis every Monday & Thursday. Stay ahead of breakout opportunities.
Disclaimer: The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Data last updated: February 11, 2025 9:45 PM UTC
ENGN Analyst Ratings & Price Targets
Based on our analysis of 9 Wall Street analysts, ENGN has a bullish consensus with a median price target of $27.50 (ranging from $16.00 to $37.00). The overall analyst rating is Strong Buy (9.1/10). Currently trading at $6.37, the median forecast implies a 331.7% upside. This outlook is supported by 9 Buy, 0 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Colin Bristow at UBS, projecting a 480.8% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
ENGN Analyst Consensus
ENGN Price Target Range
Latest ENGN Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for ENGN.
Date | Firm | Analyst | Rating | Change | Price Target |
---|---|---|---|---|---|
Dec 23, 2024 | HC Wainwright & Co. | Andres Maldonado | Buy | Initiates | $25.00 |
Dec 23, 2024 | JMP Securities | Silvan Tuerkcan | Market Outperform | Reiterates | $18.00 |
Dec 6, 2024 | JMP Securities | Silvan Tuerkcan | Market Outperform | Reiterates | $18.00 |
Nov 27, 2024 | Raymond James | Sean McCutcheon | Outperform | Initiates | $23.00 |
Nov 18, 2024 | JMP Securities | Silvan Tuerkcan | Market Outperform | Initiates | $18.00 |
Sep 24, 2024 | Oppenheimer | Leland Gershell | Outperform | Reiterates | $30.00 |
Sep 11, 2024 | Morgan Stanley | Jeffrey Hung | Overweight | Maintains | $40.00 |
Aug 28, 2024 | Oppenheimer | Leland Gershell | Outperform | Initiates | $30.00 |
Apr 22, 2024 | Wells Fargo | Yanan Zhu | Overweight | Initiates | $30.00 |
Apr 15, 2024 | Guggenheim | Manuel Navas | Buy | Initiates | $34.00 |
Mar 28, 2024 | UBS | Colin Bristow | Buy | Initiates | $37.00 |
Mar 8, 2024 | Morgan Stanley | Jeffrey Hung | Overweight | Initiates | $40.00 |
Feb 20, 2024 | Leerink Partners | Mani Foroohar | Outperform | Initiates | $31.00 |
Stocks Similar to enGene Holdings Inc.
The following stocks are similar to enGene based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
enGene Holdings Inc. (ENGN) Financial Data
enGene Holdings Inc. has a market capitalization of $322.17M with a P/E ratio of 0.0x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of -123.1%.
Valuation Metrics
Growth & Margins
Financial Health
๐ฅ Want More High-Potential Stock Ideas?
Join 5,000+ investors getting our research on stocks with massive upside potential.

enGene Holdings Inc. (ENGN) Company Overview
About enGene Holdings Inc.
Develops genetic medicines for bladder cancer.
The company operates as a clinical-stage biotechnology firm, focusing on the development of innovative genetic therapies. It generates revenue through the advancement of its lead product candidate, detalimogene voraplasmid, which targets non-muscle invasive bladder cancer patients who do not respond to existing treatments.
Based in Montreal, Canada, enGene Holdings Inc. aims to address significant unmet medical needs in bladder cancer treatment. Its unique non-viral monotherapy approach positions it within a niche market with potential for high impact and growth.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
31
CEO
Mr. Jason D. Hanson Esq., J.D.
Country
Canada
IPO Year
2023
Website
www.engene.comenGene Holdings Inc. (ENGN) Latest News & Analysis
enGene Holdings Inc. announced that its lead investigational product, detalimogene voraplasmid, is in a pivotal study for treating high-risk, BCG-unresponsive non-muscle invasive bladder cancer.
The announcement highlights enGene's pivotal study progress on a novel cancer treatment, which could significantly impact its market value and investor sentiment if successful.
enGene Holdings Inc. announced inducement equity awards as it continues a pivotal study on its investigational product, detalimogene voraplasmid, for treating high-risk bladder cancer.
enGene's pivotal study on a novel treatment for a severe cancer type could impact its stock value and attract investor interest, indicating potential for future growth or partnerships.
enGene Holdings Inc. (Nasdaq: ENGN) announced three poster presentations related to their investigational product, detalimogene voraplasmid, at an upcoming conference. The product is in a pivotal study for high-risk bladder cancer.
enGene's ongoing pivotal study and poster presentations highlight progress in treating a significant cancer type, potentially impacting its valuation and attracting investor interest in genetic therapies.
How Much Upside is Left in enGene Holdings Inc. (ENGN)? Wall Street Analysts Think 238.77%
1 month agoWall Street analysts set a price target for enGene Holdings Inc. (ENGN) suggesting a potential upside of 238.8%, supported by positive earnings estimate revisions.
A 238.8% upside in price targets suggests significant growth potential for enGene Holdings Inc. (ENGN), bolstered by positive earnings revisions, attracting investor interest.
enGene Holdings Inc. reported its financial results for the year, while its lead product, detalimogene voraplasmid, is in a pivotal study for high-risk BCG-unresponsive bladder cancer.
enGene's financial results and ongoing pivotal study highlight its potential to innovate in cancer treatment, impacting stock performance and investor sentiment in biotech.
enGene Holdings Inc. (ENGN) has been upgraded to a Zacks Rank #1 (Strong Buy), indicating positive sentiment regarding its earnings prospects.
Growing optimism and a Zacks Rank #1 indicates strong earnings potential, suggesting potential price appreciation for enGene Holdings Inc. (ENGN) shares.
Frequently Asked Questions About ENGN Stock
What is enGene Holdings Inc.'s (ENGN) stock forecast for 2025?
Based on our analysis of 9 Wall Street analysts, enGene Holdings Inc. (ENGN) has a median price target of $27.50. The highest price target is $37.00 and the lowest is $16.00.
Is ENGN stock a good investment in 2025?
According to current analyst ratings, ENGN has 9 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $6.37. Always conduct your own research and consider your investment goals before making investment decisions.
What is the price prediction for ENGN stock?
Wall Street analysts predict ENGN stock could reach $27.50 in the next 12 months. This represents a 331.7% increase from the current price of $6.37. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is enGene Holdings Inc.'s business model?
The company operates as a clinical-stage biotechnology firm, focusing on the development of innovative genetic therapies. It generates revenue through the advancement of its lead product candidate, detalimogene voraplasmid, which targets non-muscle invasive bladder cancer patients who do not respond to existing treatments.
What is the highest forecasted price for ENGN enGene Holdings Inc.?
The highest price target for ENGN is $37.00 from Colin Bristow at UBS, which represents a 480.8% increase from the current price of $6.37.
What is the lowest forecasted price for ENGN enGene Holdings Inc.?
The lowest price target for ENGN is $16.00 from at , which represents a 151.2% increase from the current price of $6.37.
What is the overall ENGN consensus from analysts for enGene Holdings Inc.?
The overall analyst consensus for ENGN is bullish. Out of 9 Wall Street analysts, 9 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $27.50.
How accurate are ENGN stock price projections?
Stock price projections, including those for enGene Holdings Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.